The CenterWatch Monthly, February 2012
Anticipating the rise of virtual drug development
With the rising cost of drug development and a continued shortage of new products entering the marketplace, the virtual pharma model is expected to become more prevalent going forward, particularly as pharma companies have shown greater interest in buying assets from virtual companies. Benefits of the virtual model include less overhead and faster…
Closing investigative site operations a complex process
In light of the shrinking investigative site landscape reported and detailed in our January issue, CenterWatch has conducted in-depth case studies of sites closing their operations. Site personnel offer insights into insights into the challenges of exiting the business and how to better manage the process. The site profiles, which each took a different path to closing shop, detail the numerous logistics involved, from ensuring patient safety and considering their employees’ futures to…
Eye On Shire
Shire is a rapidly growing, global specialty biopharmaceutical company aiming “to enable people with life-altering conditions to lead better lives.” While based in the U.K. and U.S., it also directly markets its products in over 50 countries. Shire’s stated goal is to have half of its sales originate from beyond the U.S. and European…
To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.